Chuck Yonan, PharmD

Clinician-Reported Patient Awareness of Symptoms and Severity of Tardive Dyskinesia in Patients Prescribed VMAT2 Inhibitors

Background: Vesicular monoamine transporter 2 (VMAT2) inhibitors including valbenazine are first-line therapies for tardive dyskinesia (TD), a persistent movement disorder associated with...

Leslie Lundt , MD;

Chuck Yonan , PharmD;

Rahul Dhanda , PhD;

Jonathan Meyer , MD;

Betsy Benning ;

Ericha Franey , PhD;

Edward Goldberg , MD;

10/18/2020

Concerns from Community Mental Health Center (CMHC) Patients Regarding Drug-Induced Movement Disorders: Impact on Functioning and Treatment Beliefs

Background: Drug-induced movement disorders (DIMDs) may occur in patients treated with antipsychotics. The CommonGround Program supports the recovery and healing of psychiatric outpatient...

Allison Stiles , MA, LPC;

Ericha Franey , PhD;

Edward Goldberg , MD;

Leslie Lundt , MD;

Chuck Yonan , PharmD;

Rahul Dhanda , PhD;

10/08/2020

Tardive Dyskinesia Symptom Screening in Real-World Outpatient Settings: Correlations Between Patient-, Caregiver-, and Clinician-Reported Assessments in the RE-KINECT Study

Objective: To document possible tardive dyskinesia (TD) in psychiatric outpatients, as assessed by patients, caregivers, and clinicians.

Huda Shalhoub , PhD;

Jun Chen , MS, MSc;

Caroline Tanner , MD;